Dianthus Therapeutics, Inc. (DNTH) Financial Analysis & Valuation | Quarter Chart
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myas... more
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develop... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $5.42B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Marino Garcia |
| IPO Date | 2018-06-21 | CAGR | — |
| Employees | 92 | Website | dianthustx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.01% | Total Yield | -0.01% |
DNTH chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $5.29B | P/E | -23.33 | Forward P/E | -21 | PEG | — |
| P/S | 1387.87 | P/B | 1.35 | P/CF | -10.07 | P/FCF | -10.2 |
| Sales | $1.90M | Sales 1Y | -60.77% | Sales 3Y | -49.8% | Sales 5Y | inf% |
| EPS | $-4.15 | EPS 1Y | -96% | EPS 3Y | -99.03% | EPS 5Y | -99.43% |
| Sales QoQ | 64.36% | EPS QoQ | 5.88% | Sales QoQ Avg | 51.07% | EPS QoQ Avg | -120.93% |
| Gross Margin | 93.35% | Operating Margin | -19058.97% | Profit Margin | -2616.71% | ROCE | -18.48% |
| ROA | -2% | ROE | -4% | Altman Z Score | 77.75 | Piotroski Score | 2 |
| Current Ratio | 26.1 | Quick Ratio | 26.1 | Cash Ratio | 3.21 | Op. CF Ratio | -1.42 |
| Debt/Equity | 0 | Debt/Assets | 0 | Lt Debt/Equity | 0 | Lt Debt/Cap. | 0 |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0 | Receivables Turnover | 10.78 |
| Enterprise Value | $5.29B | P/E Ratio | -23.33 |
| Forward P/E | -21 | PEG Ratio | — |
| P/S Ratio | 1387.87 | P/B Ratio | 1.35 |
| P/CF Ratio | -10.07 | P/FCF Ratio | -10.2 |
| EPS | $-4.15 | EPS Growth 1Y | -96% |
| EPS Growth 3Y | -99.03% | EPS Growth 5Y | -99.43% |
| Revenue Growth 1Y | -60.77% | Gross Margin | 93.35% |
| Operating Margin | -19058.97% | Profit Margin | -2616.71% |
| ROE | -4% | ROA | -2% |
| ROCE | -18.48% | Current Ratio | 26.1 |
| Quick Ratio | 26.1 | Cash Ratio | 3.21 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 77.75 | Piotroski Score | 2 |
Dianthus Therapeutics, Inc. (DNTH) valuation & financials
Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of $5.42B and trades at a price-to-earnings ratio of -23.3. It operates in the Healthcare sector (Biotechnology).
Dianthus Therapeutics, Inc.'s revenue grew -60.8% over the last year.
Dianthus Therapeutics, Inc.'s next earnings report is scheduled for November 5, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.94. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)